Avanos Medical (NYSE:AVNS) Issues FY 2020 Pre-Market Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its FY 2020
Pre-Market earnings guidance on Tuesday. The company provided EPS guidance of 1.00-1.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.16. The company issued revenue guidance of $732.48-746.432 million, compared to the consensus revenue estimate of $736 million.Avanos Medical also updated its FY20 guidance to $1.00-1.20 EPS.

Several research analysts have weighed in on the company. Barclays restated a sell rating and issued a $30.00 price target on shares of Avanos Medical in a research note on Tuesday, January 28th. Raymond James downgraded Avanos Medical from an outperform rating to a market perform rating in a research note on Wednesday, November 6th. Zacks Investment Research upgraded Avanos Medical from a sell rating to a hold rating and set a $46.00 price target for the company in a research note on Wednesday, October 30th. TheStreet downgraded Avanos Medical from a c- rating to a d+ rating in a research note on Monday, February 10th. Finally, ValuEngine upgraded Avanos Medical from a hold rating to a buy rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $42.67.

AVNS stock traded down $1.57 during midday trading on Wednesday, hitting $32.84. The company’s stock had a trading volume of 512,200 shares, compared to its average volume of 375,055. Avanos Medical has a 12 month low of $27.32 and a 12 month high of $50.28. The company has a quick ratio of 1.84, a current ratio of 2.51 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -36.90 and a beta of 1.52. The company has a 50 day moving average of $30.73 and a two-hundred day moving average of $34.66.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, February 25th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.02. The firm had revenue of $189.80 million during the quarter, compared to the consensus estimate of $178.58 million. Avanos Medical had a positive return on equity of 3.92% and a negative net margin of 6.20%. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.30 EPS. On average, analysts anticipate that Avanos Medical will post 1.04 earnings per share for the current fiscal year.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Featured Article: Debt-To-Equity Ratio

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.